## Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3T3 Neutral Red Uptake Phototoxicity Test (3T3 NRU-PT)</td>
<td>407–11</td>
</tr>
<tr>
<td>Abbreviated Medicine Review Process (AMRP)</td>
<td>103</td>
</tr>
<tr>
<td>Abbreviated New Drug Submissions (ANDS)</td>
<td>58</td>
</tr>
<tr>
<td>ACA see active cutaneous anaphylaxis</td>
<td></td>
</tr>
<tr>
<td>ACPM see Advisory Committee on Prescription Medicines</td>
<td></td>
</tr>
<tr>
<td>acquired immunodeficiency syndrome see HIV/AIDS</td>
<td></td>
</tr>
<tr>
<td>active cutaneous anaphylaxis (ACA)</td>
<td>331</td>
</tr>
<tr>
<td>active pharmaceutical ingredients (APIs)</td>
<td></td>
</tr>
<tr>
<td>Australia 188–9</td>
<td></td>
</tr>
<tr>
<td>drug development 13</td>
<td></td>
</tr>
<tr>
<td>global pharmaceutical market 6</td>
<td></td>
</tr>
<tr>
<td>active systemic anaphylaxis (ASA)</td>
<td>331</td>
</tr>
<tr>
<td>acute toxicity studies</td>
<td></td>
</tr>
<tr>
<td>Australia 193–4</td>
<td></td>
</tr>
<tr>
<td>Japan 135–6</td>
<td></td>
</tr>
<tr>
<td>MERCOSUR and Brazil 42–3, 48–9, 52</td>
<td></td>
</tr>
<tr>
<td>ADA see anti-drug antibodies</td>
<td></td>
</tr>
<tr>
<td>ADHD see attention deficit hyperactivity disorder</td>
<td></td>
</tr>
<tr>
<td>adjuvants 388</td>
<td></td>
</tr>
<tr>
<td>ADME studies</td>
<td></td>
</tr>
<tr>
<td>Australia 189–9</td>
<td></td>
</tr>
<tr>
<td>biologics 348–9</td>
<td></td>
</tr>
<tr>
<td>Canada 68</td>
<td></td>
</tr>
<tr>
<td>developmental and reproductive toxicology 274, 292</td>
<td></td>
</tr>
<tr>
<td>Japan 136–7</td>
<td></td>
</tr>
<tr>
<td>juvenile animal toxicity studies 304, 305–7</td>
<td></td>
</tr>
<tr>
<td>administration route and frequency 12</td>
<td></td>
</tr>
<tr>
<td>biologics 367–8</td>
<td></td>
</tr>
<tr>
<td>carcinogeticity studies 229–30</td>
<td></td>
</tr>
<tr>
<td>China 126</td>
<td></td>
</tr>
<tr>
<td>developmental and reproductive toxicology 267–8, 287–8</td>
<td></td>
</tr>
<tr>
<td>India 152–4, 158–9</td>
<td></td>
</tr>
<tr>
<td>MERCOSUR and Brazil 49–52</td>
<td></td>
</tr>
<tr>
<td>phototoxicity 413–15</td>
<td></td>
</tr>
<tr>
<td>repeated-dose toxicity studies 208–9, 211</td>
<td></td>
</tr>
<tr>
<td>vaccines 387</td>
<td></td>
</tr>
<tr>
<td>adverse drug reactions (ADR) 123–4</td>
<td></td>
</tr>
<tr>
<td>adverse event monitoring 123–4</td>
<td></td>
</tr>
<tr>
<td>adverse immunomodulation 314–21, 342</td>
<td></td>
</tr>
<tr>
<td>Advisory Committee on Prescription Medicines (ACPM) 183</td>
<td></td>
</tr>
<tr>
<td>AIDS see HIV/AIDS</td>
<td></td>
</tr>
<tr>
<td>allergenicity studies 155, 161, 163, 170</td>
<td></td>
</tr>
<tr>
<td>American Medical Association (AMA) 28</td>
<td></td>
</tr>
<tr>
<td>AMRP see Abbreviated Medicine Review Process</td>
<td></td>
</tr>
<tr>
<td>ANDS see Abbreviated New Drug Submissions</td>
<td></td>
</tr>
<tr>
<td>animal welfare</td>
<td></td>
</tr>
<tr>
<td>biologics 350</td>
<td></td>
</tr>
<tr>
<td>China 133</td>
<td></td>
</tr>
<tr>
<td>India 149–51</td>
<td></td>
</tr>
<tr>
<td>International Conference on Harmonization 22–3</td>
<td></td>
</tr>
<tr>
<td>Japan 142</td>
<td></td>
</tr>
<tr>
<td>antibody-mediated cytotoxicity 333</td>
<td></td>
</tr>
<tr>
<td>anticancer pharmaceuticals 201–2, 275–6</td>
<td></td>
</tr>
<tr>
<td>anti-drug antibodies (ADA) 337–8, 356–8, 377</td>
<td></td>
</tr>
<tr>
<td>antigenicity studies 141</td>
<td></td>
</tr>
<tr>
<td>ANVISA see Brazilian National Regulatory Agency</td>
<td></td>
</tr>
<tr>
<td>APIs see active pharmaceutical ingredients</td>
<td></td>
</tr>
<tr>
<td>area under the plasma concentration curve (AUC)</td>
<td></td>
</tr>
<tr>
<td>biologics 360</td>
<td></td>
</tr>
<tr>
<td>carcinogeticity studies 228, 234</td>
<td></td>
</tr>
<tr>
<td>repeated-dose toxicity studies 202–3, 206–7</td>
<td></td>
</tr>
</tbody>
</table>

© 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.
ARGB see Australian Regulatory Guidelines for Biologicals
ARGPM see Australian Regulatory Guidelines for Prescription Medicines
ARTG see Australian Register of Therapeutic Goods
ASA see active systemic anaphylaxis
attention deficit hyperactivity disorder (ADHD) 308
AUC see area under the plasma concentration curve
Australia 175–96
Business Process Reform scheme 181–3
Chemistry, Manufacturing and Control 188–9
clinical trials 176, 183–95
evaluation categories 180–2
evaluation fees and guidelines 183
information supplied to support inclusion of therapeutic goods 178–80
legislative backing for the TGA 176–8
nonclinical data to support clinical trials 188–95
nonclinical pharmacology and pharmacokinetics 189–90, 191
nonclinical toxicology studies 190–95
Therapeutic Goods Administration 175–83, 186–95
Australian Register of Therapeutic Goods (ARTG) 176, 177–83
Australian Regulatory Guidelines for Biologicals (ARGB) 181–2
Australian Regulatory Guidelines for Prescription Medicines (ARGPM) 178, 179
autism 382–3
autoimmunity 334–5
Best Pharmaceuticals for Children Act (BPCA) 298–300
BGTD see Biologics and Genetic Therapies Directorate
binding affinity studies 351–2, 358
bio-betters/bio-superiors 283
biocompatibility 216
Biological License Applications (BLAs) 11
biologics 347–79
biological activity and pharmacodynamics 348–9, 352, 358–9, 363–7, 374–6
biosimilars 7, 45–6, 74–7, 282–4
Canada 74–7
carcinogenicity studies 247–8, 369–70
China 130
classification and definitions for drug registration 45–6
comparability 375–7
defining a pharmacologically relevant species 350–2
developmental and reproductive toxicology 279–82, 370–1
disease models 355–6
dosage and dosage forms 364–7, 373–75
European pharmaceutical regulation 88–9
genetic toxicology 368–9
genetically modified models 353–54
immunogenicity 349, 356–8, 376–7
immunotoxicological evaluations 335, 370–1
impurities 434–5
local tolerance studies 371
pharmacokinetics/toxicokinetics 348–9, 352, 355–8, 359–62, 374–6
regulatory guidelines 347–8, 362–3, 367–73
safety pharmacology 368
species selection 349–50
study design 363–8
surrogate molecules 353
tissue cross-reactivity 371–3
unique characteristics 348–9
utilizing non-pharmacologically relevant species 355–6
Biologics and Genetic Therapies Directorate (BGTD) 60, 68, 71, 74
Biologics License Applications (BLAs) 384
biomarkers
drug development 4, 12
phototoxicity 416–17, 423–5
biosimilars 7
Canada 74–7
classification and definitions for drug registration 45–6
developmental and reproductive toxicology 282–4
BLAs see Biological License Applications
blood abnormalities 318
body weight 213
bone marrow toxicity 318–24
botanicals 125, 130, 290
BPCA see Best Pharmaceuticals for Children Act
BPR see Business Process Reform
Brazil see MERCOSUR and Brazil
Brazilian National Regulatory Agency (ANVISA) 44–54
Buehler Assay (BA) 333
Business Process Reform (BPR) scheme 181–3

CAC see Carcinogen Assessment Committee
Caesarean sectioning 288
Canada
Biologics and Genetic Therapies Directorate 60, 68, 71, 74
Summary Basis of Decision procedure 67–70, 76–7
clinical trial applications 58, 60, 66, 70–4
generic drugs 74
Good Laboratory Practices 66–7
International Conference on Harmonization 64–5
Natural Health Products Directorate 60
organization 58–60
orphan drugs 77–8
regulatory framework for drug approval 60–4
special regulatory considerations 74–8
subsequent entry biologics 74–7
Therapeutic Products Directorate 58–60, 71
Carcinogen Assessment Committee (CAC) 224, 240
carcinogenicity studies 219–54
age of animals 230–1
alternative models to 2-year mouse studies 244–7
Australia 194
biologics 247–8, 369–70
Canada 68, 77
China 130–1
communicating results in product labels 251
control groups 231
development of study plan 241
dose selection 232–4, 239
drug and dosage formulation analysis 230
gene expression profiling 227
genetic toxicology 233, 249, 255, 262–3
group size 230–1
hormonal imbalances 226

BPCA see Best Pharmaceuticals for Children Act
BPR see Business Process Reform
Brazil see MERCOSUR and Brazil
Brazilian National Regulatory Agency (ANVISA) 44–54
Buehler Assay (BA) 333
Business Process Reform (BPR) scheme 181–3

CAC see Carcinogen Assessment Committee
Caesarean sectioning 288
Canada
Biologics and Genetic Therapies Directorate 60, 68, 71, 74
Summary Basis of Decision procedure 67–70, 76–7
clinical trial applications 58, 60, 66, 70–4
generic drugs 74
Good Laboratory Practices 66–7
International Conference on Harmonization 64–5
Natural Health Products Directorate 60
organization 58–60
orphan drugs 77–8
regulatory framework for drug approval 60–4
special regulatory considerations 74–8
subsequent entry biologics 74–7
Therapeutic Products Directorate 58–60, 71
Carcinogen Assessment Committee (CAC) 224, 240
carcinogenicity studies 219–54
age of animals 230–1
alternative models to 2-year mouse studies 244–7
Australia 194
biologics 247–8, 369–70
Canada 68, 77
China 130–1
communicating results in product labels 251
control groups 231
development of study plan 241
dose selection 232–4, 239
drug and dosage formulation analysis 230
gene expression profiling 227
genetic toxicology 233, 249, 255, 262–3
group size 230–1
hormonal imbalances 226

immunosuppression 227
impurities 443
India 155, 165–6, 170
indicators of cellular proliferation 225–6
International Conference on Harmonization 20, 23
Japan 138, 140
MERCOSUR and Brazil 44, 53
metabolite profiles 228
pathological evaluations 235–7, 242–4
performance of study 241–4
photocarcinogenicity 393–7, 399, 417–18
positive results and human safety 249–51
protocol/study plan 228–51
regulatory guidelines 222–3
regulatory implications of positive results 248–9
route of administration 229–30
satellite groups for mechanistic studies 237
species and strain selection 228–9
timing of regulatory submission 223–4
toxicokinetics 227–8, 234
CAT see Committee for Advanced Therapies
CBER see Center for Biologics Evaluation and Research
CCM see Certification Committee for Drugs
CCMO see Central Committee for Human Research
CDE see Center for Drug Evaluation
CDER see Center for Drug Evaluation and Research
CDR see Center for Drug Re-evaluation
CDSCO see Central Drugs Standard Control Organization
cell-mediated immunity (CMI) assay 325
cellular proliferation 225–6
Center for Biologics Evaluation and Research (CBER) 434–5
Center for Drug Evaluation (CDE) 123–4, 129–31
Center for Drug Evaluation and Research (CDER) 229, 240, 394–7, 400, 434–5, 440
Center for Drug Re-evaluation (CDR) 124
Center for Medicare and Medicaid Services (CMS) 6
Central Committee for Human Research (CCMO) 86
Central Drugs Standard Control Organization (CDSCO) 147
centralized regulatory procedures 85–6
Certification Committee for Drugs (CCD) 124
CEU see Clinical Evaluation Unit
CFR see Code of Federal Regulations
chemical intermediates 6
Chemistry, Manufacturing and Control (CMC) 33–4, 188–9
China 117–34
affiliated organizations of the SFDA 123–6
categorization of pharmaceuticals 125–7
good laboratory practice 120, 122, 131–3
import drug applications and approval procedure 119, 121, 127–9
pharmaceutical applications 125–8
pharmaceutical market 117–18
phototoxicity 396
provisions for drug registration 122
registration process 125
State Food and Drug Administration 119, 121, 123–33
testing guidelines and safety evaluation 129–31
chiral pharmaceuticals 141
CHMP see Committee for Medicinal Products for Human Use
chronic toxicity studies
Japan 135–6
MERCOSUR and Brazil 43–4, 48
repeated-dose toxicity studies 199
CIE/ISO standards 424–4
Clinical Evaluation Unit (CEU) 109
clinical trial applications (CTAs) 12–15
Canada 58, 60, 66, 70–4
China 127
content and format 72–3
history and regulations 70–1
pre-submission meetings and consultations 71–2
review process 71–4
Clinical Trial Exemption (CTX) scheme 176, 183–5, 186–7
Clinical Trial Facilitatory Group (CTFG) 86
Clinical Trial Notification (CTN) scheme 183–7
clinical trials
Australia 176, 183–95
Chemistry, Manufacturing and Control 188–9
China 119, 127
developmental and reproductive toxicology 274–5, 277, 285
European pharmaceutical regulation 86–96
Food and Drug Administration 35–7
generic toxicology 261
impurities 443
India 152–4, 173
International Conference on Harmonization 24
juvenile animal toxicity studies 302–3
nonclinical pharmacology and pharmacokinetics 189–90
nonclinical toxicology studies 190–5
phototoxicity 400
repeated-dose toxicity studies 200–202
risk mitigation 89–96
South Africa 99–100
vaccines 385–6, 389–90
Cluster Medicines Regulatory Affairs 103
Cmax
biologics 360–61
carcinogenicity studies 228, 234
repeated-dose toxicity studies 204, 206–8
CMC see Chemistry, Manufacturing and Control
CMI see cell-mediated immunity
CMS see Center for Medicare and Medicaid Services
CNS see National Health Council
combination drug products 204–205, 291–3
Committee for Advanced Therapies (CAT) 84–5
Committee for Medicinal Products for Human Use (CHMP) 11
immunotoxicological evaluations 338
juvenile animal toxicity studies 301
nonclinical testing for clinical trials 88–90
phototoxicity 395–7
scientific structure of the EMA 83–6
vaccines 385–6
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) 149–51
Common Technical Document (CTD) format 33–4, 86, 180–1, 189
comparability of biologics 375–7
complementary medicines 179
contraceptives 277–8, 290
Index 453

contract research organizations (CROs) 188
control groups 231, 288
CPCSEA see Committee for the Purpose of Control and Supervision of Experiments on Animals
CPMT see Common Technical Document
CROs see contract research organizations
CRS see cytokine release syndrome
CTAs see clinical trial applications
CTD see Common Technical Document
CTFG see Clinical Trial Facilitatory Group
CTL see cytotoxic T cell response
CTN see Clinical Trial Notification
CTX see Clinical Trial Exemption
cytogenetic assays 164–5
cytokine release syndrome (CRS) 336–7
cytotoxic T cell response (CTL) assay 325

DART see developmental and reproductive toxicity
decentralized regulatory procedures 85–6
degradants 434–5
delayed-type hypersensitivity (DTH) 325, 333
Department of Scientific and Industrial Research (DSIR) 146
DESI see Drug Efficacy Study Implementation
developmental immunotoxicology (DIT) 338–42
developmental and reproductive immunotoxicology (DART) 14–15, 265–96
anticancer pharmaceuticals 275–6
Australia 194
biologics 279–82, 370–1
biosimilars 282–84
botanicals 290
Canada 68, 77
combination drug products 291–3
contraceptive steroids 290
developmental toxicity or embryotoxicity studies 270–2
disease indication 275–9
European pharmaceutical regulation 88, 93
excipients 293
fertility and general reproductive performance study 266–8
human insulin analogues 278–9
immunotoxicological evaluations 340
India 155, 159–60, 169
Japan 138
juvenile animal toxicity studies 305
metabolite profiles 276, 293
pharmaceutical characteristics 279–91
prenatal and postnatal study 268–70
reproductive potential 273–5
study design 266–72
synthetic sex steroids used in food-producing animals 291
timing of preclinical DART studies 273–5
topical drugs for STDs or vaginal contraceptives 277–8

topical microbicides for viral STDs 277–8
vaccines 283–9, 388
diabetes mellitus 278–9
DIC see disseminated intravascular coagulopathy
dietary supplements 58, 60
diethylene glycol 28, 433
DINs see Drug Identification Numbers
disease models 355–6
disseminated intravascular coagulopathy (DIC) 337
dose range finding (DRF) studies 156, 193–4, 270
DIT see developmental immunotoxicology
dosage and dosage forms 12
biologics 364–7, 373–5
carcinogenicity studies 230, 232–4, 239
vaccines 387
drug development
Australia 175–6, 188
developmental and reproductive toxicology 277–8
European pharmaceutical regulation 79–80, 89–96
Food and Drug Administration 31–4
genetic toxicology 256–61
global pharmaceutical market 3–10
India 146–7, 148–9
MERCOSUR and Brazil 41–55
paediatric populations 297–310
repeated-dose toxicity studies 199–218
vaccines 381–92
Drug Efficacy Study Implementation (DESI) programme 30
Drug Identification Numbers (DINs) 60, 66, 71
drug metabolites see metabolite profiles
Drug Safety and Evaluation Branch (DSEB) 179–80
DSIR see Department of Scientific and Industrial Research
DTH see delayed-type hypersensitivity

ECAC see Executive Carcinogenicity Assessment Committee
ECG see electrocardiography
eCTD see electronic Common Technical Dossier
EDL see Essential Drugs List
EFD see embryo–foetal development efficacy studies
Food and Drug Administration 28
MERCOSUR and Brazil 47
EFPIA see European Federation of Pharmaceutical Industry Associations
EFTA see European Free Trade Association
electrocardiography (ECG) 139–43, 214
electronic Common Technical Dossier (eCTD) 86, 181
ELISA see enzyme linked immunosorbent assay
EMA see European Medicines Agency
embryo–foetal development (EFD) studies biologics 370
impurities 443, 445–6
embryotoxicity studies Canada 68–9
developmental and reproductive toxicology 270–2, 274, 276, 281–2
drug development 14–15
International Conference on Harmonization 22
MERCOSUR and Brazil 44
enhanced pre- and postnatal development (ePPND) studies 282, 370
Environmental Protection Agency (EPA) 148, 298
enzyme linked immunosorbent assay
(ELISA) 326, 336
EPA see Environmental Protection Agency
ePPND see enhanced pre- and postnatal development
Essential Drugs List (EDL) 104
ethics committees 86–7
European Federation of Pharmaceutical Industry Associations (EFPIA) 18
European Free Trade Association (EFTA) 81, 82
European Medicines Agency (EMA) 80, 82–6
carcinogenicity studies 222–3, 251
clinical trials 93–6
developmental and reproductive toxicology 278
immunotoxicology 261–3
India 172–3
individual country regulatory agencies/authorities’ roles 88–9
juvenile animal toxicity studies 300–302, 304, 307, 309
phototoxicity 395–7, 411
regulatory process in the EU 85–6
repeated-dose toxicity studies 204, 208–9, 215
risk mitigation 90
role in the regulation of medicines 82–3
scientific structure 83–5
vaccines 385–6, 388–90
European pharmaceutical regulation
clinical trials 86–96
definitions 81–2
European Medicines Agency 82–5
historical context 79–81
individual country regulatory agencies/authorities’ roles 87–9
nonclinical testing 79–97
regulation of medicinal products in the EU 82–6
regulatory process 85–6
risk mitigation 89–96
EWGs see Expert Working Groups
ex vivo models 92–3
excipients 293
Executive Carcinogenicity Assessment Committee (ECAC) 240
 Expedited Review Process 104
Expert Working Groups (EWGs) 19–22
extractables 439–42
false negatives 405
false positives 402–6
Fast-track Review Process 104
FD&C Act see Federal Food, Drug, and Cosmetic Act
FDA see Food and Drug Administration
Federal Food, Drug, and Cosmetic Act (FD&C Act) 10, 28–9
fertility studies 14–15
developmental and reproductive toxicology 266–8, 273, 285
India 155, 159–60, 169

FFDCA see Federal Food, Drug, and Cosmetic Act

FIH see first-in-human

FIPnets see fully integrated pharmaceutical networks

first-in-human (FIH) trials
biologics 355–6, 362, 364, 373–5
dose estimation 95–6
European pharmaceutical regulation 89–92, 94, 95–6
Food and Drug Administration 31, 37
immunotoxicological evaluations 335
International Conference on Harmonization 24
flow cytometry 323–4, 327, 351
follow-on protein products (FOPPs) see biosimilars

Food and Drug Administration (FDA) 27–39
Australia 190, 194
biologics 371–3
carcinogenicity studies 223–4, 228, 232, 238–42, 249, 251
China 129–33
Common Technical Document format 33–4
devolutional and reproductive toxicology 265, 276–8, 292–3
drug development 5, 10–11
European pharmaceutical regulation 95
FDA Modernization Act 30–1
first-in-human trials 31, 37
in silico models 261–2
in vitro and in vivo assays 256–8, 259–61
India 155, 163–5, 170
Japan 138, 141–2
MERCOSUR and Brazil 48–9, 53
nonclinical drug development 31–4
pharmacokinetics 34
quality and purity of drug products 431–4, 436, 439–43, 446
repeated-dose toxicity studies 204–5, 208–9
toxicity testing 34–7
vaccines 383–6, 388–90
food-producing animals 291
FOPPs see biosimilars
formulations
carcinogenicity studies 230
phototoxicity 413–15
repeated-dose toxicity studies 210–11
fully integrated pharmaceutical networks (FIPnets) 6

GCP see Good Clinical Practices
gene expression profiling 227, 250
General Office Of Drugs (GGMED) 44–5
generalized systemic immune complex disease 337–9
generic drugs
Canada 74
China 119
classification and definitions for drug registration 45–6
global pharmaceutical market 6, 7
India 145
genetic sequence databases 350
genetic toxicology 255–64
Australia 192–3
biologics 368–9
Canada 69, 77
carcinogenicity studies 233, 246, 255
China 130–1
empirical testing 262
genotoxic impurities 261–3
ICH genetic toxicology battery 258–9
impurities 436, 438, 445
in silico models 261–2

India 155, 163–5, 170
Japan 138, 141–2
MERCOSUR and Brazil 48–9, 53
photogenotoxicity 393–7
regulatory decision making 263
safety levels for impurities 262–3
timing 261
vaccines 389
genetically modified models
biologics 353–4
carcinogenicity studies 244–7
developmental and reproductive toxicology 270, 281
GGMED see General Office Of Drugs
Global Cooperation Group 65

global pharmaceutical market
  current context 6–9
  drug classes 8–9
  drug development 3–10
  future directions 9–10
  growth and globalization 3–4, 6–7

GLP see Good Laboratory Practices
glycosylation 360

GMP see Good Manufacturing Practices

Good Clinical Practices (GCP)
  Australia 184
  Canada 67, 71
  China 120
  India 148
  South Africa 99, 106

Good Laboratory Practices (GLP) 12–13
  Australia 185, 191, 193
  biologics 362–3, 372
  Canada 66–7
  China 120, 122, 131–3
developmental and reproductive toxicology 278

European pharmaceutical regulation 80, 93

Food and Drug Administration 31, 33

immunotoxicological evaluations 325, 329–30, 336
  India 146–7, 168–71
  Japan 136

repeated-dose toxicity studies 199, 204, 210
  South Africa 99

Good Manufacturing Practices (GMP)
  Australia 187, 188, 191
  China 120
  India 148
  quality and purity of drug products 434
  repeated-dose toxicity studies 204, 210
  South Africa 99, 104–6

Good Supply Practices (GSP) 120
guinea pig maximization test (GPMT) 163, 333

HIN1 virus 69–70
H5N1 virus 70

Health Canada 57–60, 66–70, 77
Health and Environmental Sciences Institute (HESI) 245–6, 305

HED see human equivalent dose
herbal drugs 45–6, 48–51

HESI see Health and Environmental Sciences Institute

hexachlorophene 405–6

Highest Non-Severely Toxic Dose (HNSTD) 37, 201

histopathology
  carcinogenicity studies 219, 235–6, 242–4
  immunotoxicological evaluations 321–3
  repeated-dose toxicity studies 215
  vaccines 387–8

HIV/AIDS 277

HNSTD see Highest Non-Severely Toxic Dose

homoeopathic drugs 45–6, 48, 60

hormonal imbalances 226

Hras2 model 244–7

HREC see Human Research Ethics Committee
human equivalent dose (HED) 37, 374
human immunodeficiency virus (HIV) 277
human insulin analogues 278–9

Human Research Ethics Committee (HREC) 183–7, 190–3

hygiene hypothesis 382

hypersensitivity studies
  immunotoxicological evaluations 327, 329, 331–4
  India 155, 163, 170

IACUC see Institutional Animal Care and Use Program

IAEC see Institutional Animal Ethics Committee

IBSC see Institutional Biosafety Committee

ICD see immune complex disease

ICDRA see International Conference of Drug Regulatory Authorities

ICH see International Conference on Harmonization

IDRH see immune-mediated drug-related hypersensitivity

IFPMA see International Federation of Pharmaceutical Manufacturing Authorities

ILSI see International Life Science Institute

immediate hypersensitivity 331–2

immune complex disease (ICD) 337–8

immune complex-mediated hypersensitivity 333

immune-mediated drug-related hypersensitivity (IDRH) 332
immune system overload 382
immunogenicity studies
  biologics 337–9, 349, 356–8, 376–7
  Canada 70
developmental and reproductive
toxicology 280
vaccines 386, 388
immunological endpoints 289, 315, 376–7
immunomodulation 314–21, 335–5, 342
immunophenotyping 327–8
immunosuppression 227
immunotoxicological evaluations 313–42
  adverse or unintended immunomodula-
tion 314–30, 342
anti-drug antibodies 337–8
assay selection 325–7
autoimmunity 334–5
biologics 335–8, 370–1
clinical pathology 316–21
clinical signs 315–16
developmental immunotoxicology 338–42
generalized systemic immune complex
disease 337–8
histopathology 321–3
hypersensitivity 327, 329, 331–4
ICH S8 Weight of Evidence Review
  314–20, 325, 327–8, 330, 335
immunogenicity 337–8
immunomodulatory drugs 335
organ weights 322
regulatory expectations 314–34
standard toxicology studies 315, 323–25
study design 329–30, 340–2
vaccines 389
IMPD see Investigational Medicinal Product
  Dossier
import drug applications 119, 121, 127–9
impurities 141–2
data collection 444
developmental and reproductive
toxicology 276
drugs and biologics 434–5
exceptions 444
extractables and leachables 439–42
 genetic toxicology 261–3
metabolite profiles 442–6
new drug products 437–8
new drug substances 435–7
nonclinical evaluation 442–6
quality and purity of drug products 431–4
regulatory decision making 445–6
residual solvents 438–9
safety assessment strategy 443
systemic exposure threshold 443
timing of clinical trials 443
in silico models
carcinogenicity studies 250
drug development 12
 genetic toxicology 261–2
impurities 441, 443
in vitro models
biologics 356, 358–9, 364, 367, 375–6
Canada 68
carcinogenicity studies 247–8
drug development 12, 14
European pharmaceutical regulation 88–93
 genetic toxicology 256–8, 259–61
impurities 436, 438, 441, 443–4
India 148–9, 163–4
phototoxicity 400–411
in vivo models
biologics 355–6, 358–9, 364, 367, 375–6
Canada 68
carcinogenicity studies 247–8
drug development 12–14
European pharmaceutical regulation 91–3,
94–5
 genetic toxicology 256–60, 259–61
impurities 441, 444–5
India 148–9, 163–5
phototoxicity 401–404, 411–18
South Africa 111
India 145–73
allergenicity/hypersensitivity studies 155,
161, 163, 170
animal pharmacology 166–8
animal toxicology 154–66
carcinogenicity studies 155, 165–6, 170
clinical trials 152–4, 173
data requirements for clinical study
  approval 151–4
drug development 146–7, 148–9
fertility studies 155, 159, 169
generic toxicology 155, 163–5, 170
Good Laboratory Practices 146–7, 168–71
key approval requirements 148–51
local tolerance studies 154–5, 161–3, 169
Mutual Acceptance of Data 147, 171
nonclinical safety assessment 149–51
quality systems 147–8
India (Continued)
reproduction and developmental toxicity studies 159–60, 169
safety assessment test facilities 171–3
Schedule Y and international guidelines 168–70
INDs see Investigational New Drugs
inflammation 320, 421
infliximab 353
informal working groups (IWGs) 20–1
inhalation insulin 308
inhalation toxicity studies 154, 162–3
Institutional Animal Care and Use Program (IACUC) 150
Institutional Animal Ethics Committee (IAEC) 150–1
Institutional Biosafety Committee (IBSC) 151
insulin 308
insulin analogues 278–9
International Conference of Drug Regulatory Authorities (ICDRA) 18
International Conference on Harmonization (ICH)
adoption process 65
animal welfare and alternative methods 22–3
Australia 183–4, 190, 192, 194–5
biologics 347–8, 362–3, 367–71
Canada 64–5
carcinogenicity studies 220–3, 227–8, 232, 238, 244–51
China 129–31
Common Technical Document format 33–4
developmental and reproductive toxicology 265–75, 279–80, 282, 285, 293
drug development 5, 11, 13
European pharmaceutical regulation 80–2, 87–9, 93–4
genetic toxicology 255–6, 258–62
Guidance Document S5(R2) 285
history and nonclinical guidelines 17–25
ICH M4 Common Technical Dossier 25, 72
ICH S6(R1) 347–8, 362–3, 367, 371
ICH S8 Weight of Evidence Review 314–20, 325, 327–9, 330, 335
immunotoxicological evaluations 314–20, 325, 327–8, 331, 338
Japan 136, 140–2
juvenile animal toxicity studies 299, 301–304
organizational structure 19–20
phototoxicity 395, 400
quality and purity of drug products 433–38, 441–4
regional differences 22, 24
repeated-dose toxicity studies 200–201, 204–5, 209
safety topics 19
“Six Pack” countries 18, 21–2
South Africa 105
vaccines 385, 389
International Federation of Pharmaceutical Manufacturing Authorities (IFPMA) 18
International Life Science Institute (ILSI) 305
Investigational Medicinal Product Dossier (IMPD) 87
Investigational New Drug (IND)
Canada 70–1, 73
developmental and reproductive toxicology 277–8
drug development 5, 11, 13–15
Food and Drug Administration 29–34
global pharmaceutical market 10
impurities 437
India 152–3, 172–3
repeated-dose toxicity studies 199, 204–205, 210
ISO/CIE standards 423–5
IWGs see informal working groups
Japan 135–43
approval application of new drugs 136–9
current nonclinical safety guidelines 139
history of nonclinical safety assessment regulation 135–6
nonclinical safety studies for drug approval 136–9
phototoxicity 396
juvenile animal toxicity studies 297–310
adequacy of existing data for paediatric populations 307
data review and decision making 307–9
EU regulation 300–311
guidance for conduct 301–2
nonclinical juvenile safety testing 308–9
regulatory environment 298–302
strategies for decision making 304–7
Index 459

study design 304, 306–7
two species comparative safety testing 309
US paediatric laws 298–300

lactation 113
LD50 see lethal dose
leachables 439–42
less-than-effective (LTE) drugs 30
lethal dose (LD50) tests 20, 156, 200
local lymph node assay (LLNA) 163, 332–3
local tolerance studies
biologics 371
Canada 68, 70, 77
India 154–5, 161–3, 169
Japan 138, 141
vaccines 387
LTE see less-than-effective
lymphocyte transformation test (LTT) 335

MAAs see Market Authorization Applications
mAb see monoclonal antibodies
MABEL see Minimum Anticipated Biological Effect Level
macroscopic examination 214, 272
MAD see Mutual Acceptance of Data
margin of exposure (MOE) 202
margin of safety (MOS) 202–3
Market Authorization Applications (MAAs) 11, 223–4, 300–301
maximum recommended human dose (MRHD) 225, 233–4, 239–40, 249, 251
maximum recommended starting dose (MRSD) 373–4
maximum tolerated dose (MTD)
biologics 365
carcinogenicity studies 223, 224, 232–3, 247
repeated-dose toxicity studies 156, 193–4, 200, 201, 209
MCC see Medicines Control Council
mean photo effect (MPE) 408–11
Measles-Mumps-Rubella (MMR) vaccine 382–3
MED see minimal erythema dose
medical devices 216
Medical Ethical Evaluation Committees (METC) 86
Medicine Registration Forms (MRF) 105–8
Medicines Control Council (MCC) 99, 101–9
Medicines and Healthcare products Regulatory Agency (MHRA) 81, 88–9
Medicines Regulatory Authority (MRA) 99
MERCOSUR and Brazil
acute toxicity studies 42–3, 48–9, 52
chronic toxicity studies 43–4, 48
classification and definitions for drug registration 45–6
CNS Resolution No. 251/1997 53
comparison with other agencies and harmonization institutes 51–3
pharmacodynamics 42, 48
pharmacokinetics 42, 48
regional drug registration 53–4
regulatory factors 44–8
repeated-dose toxicity studies 42–3, 48–50, 53
requirements for drug registration 48–51
metabolite profiles
carcinogenicity studies 228
developmental and reproductive toxicology 276, 293
nonclinical evaluation 442–6
regulatory decision making 445–6
safety assessment strategy 443
safety evaluation in Japan 140
systemic exposure threshold 443
METC see Medical Ethical Evaluation Committees
methoxypsoralens (MOP) 405–6, 415–16, 419–22
MHLW see Ministry of Health, Labor and Welfare
MHRA see Medicines and Healthcare products Regulatory Agency
MHRD see maximum recommended human dose
microdosing 24, 204
MIGET see mouse IgE test
minimal erythema dose (MED) 412–14
Minimum Anticipated Biological Effect Level (MABEL) 37, 88, 95–6, 373–4
minimum lethal dose (MLD) 156
Ministry of Health, Labor and Welfare (MHLW) 35, 135–6, 139
Ministry of Science and Technology (MST) 133
MLD see minimum lethal dose
MMR see Measles-Mumps-Rubella
MOC see margin of safety
mode of action 91
MOE see margin of exposure
monoclonal antibodies (mAb)
devotional and reproductive
toxicology 282
immunotoxicological evaluations 370–1
nonclinical testing for clinical trials 88–9
pharmacokinetics/toxicokinetics 361
species selection 349–50
study design 366
utilizing non-pharmacologically relevant
species 355–6, 358
MOP see methoxypsoralens
mouse IgE test (MIGET) 332
MPE see mean photo effect
MR see mutual recognition
MRA see Medicines Regulatory Authority
MRF see Medicine Registration Forms
MRSD see maximum recommended starting
dose
MST see Ministry of Science and Technology
MTD see maximum tolerated dose
Mutual Acceptance of Data (MAD) 66, 147,
171, 191
mutual recognition (MR) procedures 85
National Association of Testing Authorities
(NATA) 191
National Compliance Monitoring Authority
(NGCMA) 168–71
National Formulary (NF) 432–3
National Health Council (CNS) 45–6, 53
National Institute for the Control
of Pharmaceutical and Biological
Products (NIFDC) 119, 122,
124–5, 127
National Institutes Health (NIH) 9
national reference standards 125
National Toxicology Program (NTP) 220
Natural Health Products Directorate
(NHPD) 60
natural health products (NHPs) 58, 60
natural killer (NK) cells 327
NCEs see new chemical entities
NDAs see New Drug Applications
NDSs see New Drug Submissions
new chemical entities (NCEs)
India 149–50
repeated-dose toxicity studies 200, 205
South Africa 103
New Drug Applications (NDAs) 11
carcinogenicity studies 223–4
China 120–2
Food and Drug Administration 29–30, 32
impurities 437
New Drug Submissions (NDSs) 58, 66, 72–3
new molecular entities (NMEs)
developmental and reproductive
toxicology 291–3
drug development 11
global pharmaceutical market 7, 9–10
immunotoxicological evaluations 314,
317–18
repeated-dose toxicity studies 200
new pharmaceutical products 45–6
NF see National Formulary
NGCMA see National Compliance Monitoring
Authority
NHPD see Natural Health Products Directorate
NHPs see natural health products
NIFDC see National Institute for the Control
of Pharmaceutical and Biological
Products
NK see natural killer
NMEs see new molecular entities
no observable adverse effect level
(NOEL) 20
Australia 194
biologics 362, 364, 373–75
European pharmaceutical regulation 95–6
Food and Drug Administration 37
immunotoxicological evaluations 329
MERCOSUR and Brazil 43
repeated-dose toxicity studies 201, 204
no observable effect level (NOEL) 20
European pharmaceutical regulation 89
genetic toxicology 260
juvenile animal toxicity studies 305
repeated-dose toxicity studies 201
non-prescription drugs see over-the-counter
medications
Notice of Compliance (NOC) 71, 77–8
Notice of Opportunity for a Hearing
(NOHH) 30
NTP see National Toxicology Program
OECD see Organization for Economic
Cooperation and Development
ofloxacin 405
ophthalmologic examinations 214
Index 461

Organization for Economic Cooperation and Development (OECD) 25
Australia 191
Canada  66–7
European pharmaceutical regulation 80–1
genetic toxicology 256–7
India 147, 148, 158, 171–3
juvenile animal toxicity studies 298
phototoxicity 407–11
repeated-dose toxicity studies 215
orphan drugs 77–8
Ouro Preto Protocol 42
over-the-counter (OTC) medications
  Australia 179
  Canada 58, 67
  China 124
  European pharmaceutical regulation 82
repeated-dose toxicity studies 204

p53+/− model 245–7
PABA see para-amino benzoic acid
packaging materials 440–1
Paediatric Committee (PDCO) 84, 300–301
Paediatric Investigation Plan (PIP) 300–301
paediatric populations
  data review and decision making 307–9
developmental and reproductive
toxicoology 275, 276
drug development 297–310
EU regulation 300–301
immunotoxicological evaluations 338–41, 342
Japan 141
juvenile animal toxicity studies 297–310
regulatory environment 298–302
strategies for decision making 304–7
US paediatric laws 298–300
PAHs see polycyclic aromatic hydrocarbons
PALS see periarteriolar lymphoid sheath
para-amino benzoic acid (PABA) 405–6
parenteral drugs 154, 162
passive cutaneous anaphylaxis (PCA) 331
Pathology Peer Review 243–4
Pathology Working Group (PWG) 244
PCA see passive cutaneous anaphylaxis
PDCO see Paediatric Committee
PDEs see permissible daily exposures
PDUFA see Prescription Drug Users Fee Act
Pediatric Research Equity Act (PREA) 298–300
periarteriolar lymphoid sheath (PALS) 322–3
perinatal toxicity studies 44, 68, 160, 340
permissible daily exposures (PDEs) 439
Pharmaceutical Inspection Co-operation Scheme (PIC/S) 107
Pharmaceuticals and Medical Devices Agency (PMDA) 11, 136, 139–40, 143
pharmacodynamics
  biologics 348–9, 352, 355–9, 363–7, 374–6
developmental and reproductive
toxicoology 279, 282, 286–7
European pharmaceutical regulation 92–4, 95
MERCOSUR and Brazil 42, 48
South Africa 110
pharmacokinetics/toxicokinetics
  Australia 189–90, 191
  biologics 348–9, 352, 355–8, 359–62, 374–6
  Canada 68–9
carcinogenicity studies 227–8, 234
  China 129–31
developmental and reproductive
toxicoology 272, 274, 278–9, 292
European pharmaceutical regulation 92–4, 95
genetic toxicology 256
impurities 446
India 152, 154–5
Japan 136–7
juvenile animal toxicity studies 304, 306–7
MERCOSUR and Brazil 42, 48
phototoxicity 415
repeated-dose toxicity studies 202–203, 206–7
South Africa 110
Pharmacology and Toxicology Coordinating Committee (PTCC) 435
pharmacovigilance 83–4
photocarcinogenicity 393–7, 399, 417–18
photo co-carcinogenesis 418–23
photogenotoxicity 393–7
photoirritancy factor (PIF) 407, 409–11
photosensitization 334
phototoxicity 393–425
3T3 Neutral Red Uptake Phototoxicity Test 407–11
biomarkers 416–17, 423–25
drugs and drug classes of concern 396, 398
evaluation of phototoxic responses 415–17
phototoxicity (Continued)

- FDA photosafety testing guidance 397–417
- formulation administration and light exposure 413–15
- in vitro models 400–411
- in vivo models 401–404, 411–18

India 155, 161

Japan 140

light sources for phototoxicity testing 412–13

photo co-carcinogenesis 418–23

photocarcinogenicity 393–7, 399, 417–18

photogenotoxicity 393–7

red blood cell haemolysis test 404–407

study design 418

yeast test 400–404

PIC/S see Pharmaceutical Inspection Co-operation Scheme

PIF see photoirritancy factor

PIP see Paediatric Investigation Plan

platelets 317

PLNA see popliteal lymph node assay

PMDA see Pharmaceuticals and Medical Devices Agency

polycyclic aromatic hydrocarbons (PAHs) 421

popliteal lymph node assay (PLNA) 335

post-marketing phase IV trials 99–100, 152–3

postnatal toxicity studies 44, 68, 268–70, 282, 306, 340, 370

PPSR see proposed paediatric study requests

PQRI see Product Quality Research Institute

PREA see Pediatric Research Equity Act

pregnancy

- developmental and reproductive toxicology 275

- immunotoxicological evaluations 338–42

- International Conference on Harmonization 24

- safety assessment in South Africa 113

see also teratogenicity

prenatal toxicity studies 268–70, 282, 370

Prescription Drug Users Fee Act (PDUFA) 30

prescription medicines 178–9, 183

pre-submission meetings and consultations 71–2

previously-marketed drugs 204, 291–2

Priority Review Policy 77

product labels 251

Product Quality Research Institute (PQRI) 441

proposed paediatric study requests (PPSR) 299

protein products see biologics

psoralens 405–6, 415–16, 419–22

PTCC see Pharmacology and Toxicology Coordinating Committee

PWG see Pathology Working Group

QT interval 139–40, 214

quality assurance (QA) 147–8

quality testing 384–5

Quantitative Structural Activity Relationships (QSAR) 262

quasi-drugs 11

RA see retinoic acid

rapporteurs 85–6

RBC see red blood cell

RBDs see reference biologic drugs

RCGM see Review Committee on Genetic Manipulation

reactive oxygen species (ROS) 140

rectal tolerance tests 162

red blood cell (RBC) haemolysis test 404–7

reference biologic drugs (RBDs) 74–7

re-inventing government initiatives (RIGO) 30

REMS see risk evaluation and mitigation strategies

repeated-dose toxicity studies 13–14, 199–218

animal model selection 205–6

anticancer therapeutics 201–2

assessment of systematic exposure 202–3

Australia 193–4

biologics 363–4

Canada 70, 76–7

combination drug products 205

developmental and reproductive toxicology 267–8, 280

dose and administration 208–9

dose selection 209–10

drug substance and drug formulation 210–11

duration and timing 200–201

exploratory INDs and microdosing 204

Food and Drug Administration 34, 35
Index

- group size 206–8
- impurities 436, 438
- India 156–9, 169
- International Conference on Harmonization 20, 23
- Japan 138
- MERCOSUR and Brazil 42–3, 48–50, 53
- nonclinical drug development 199–218
- qualification of drug substance and product 203
- study design 205–10
- study observations and assessments 211–16
- vaccines 387
- reproductive toxicology see developmental and reproductive toxicology
- residual solvents 438–9
- respiratory hypersensitivity 331–2
- retinoic acid (RA) 420–21
- Review Committee on Genetic Manipulation (RCGM) 151
- RIGO see re-inventing government initiatives
- risk evaluation and mitigation strategies (REMS) 10
- risk mitigation 89–96
- ROS see reactive oxygen species
- Routine Review Process 103

- safety pharmacology
  - biologics 368
  - European pharmaceutical regulation 93–4
  - India 166–8
  - Japan 137
- SAP see Special Access Programme
- SAR see Structural Activity Relationships
- satellite groups for mechanistic studies 237
- saturated absorption 233
- SBD see Summary Basis of Decision
- SBIR see small business innovation and research
- SBRA see Summary Basis for the Registration Application
- SCC see Standards Council of Canada
- Schedule Y guidelines 168–70
- Scientific Advice procedures 84
- Scientific Research and Experimental Development (SRED) tax credits 57–8
- SDA see State Drug Administration
- SEBs see subsequent entry biologics
- severe adverse reactions 90
- severely toxic dose (STD) 201
- sexually transmitted diseases (STDs) 277–8
- single-dose toxicity studies 13–14
  - Canada 76–7
  - Food and Drug Administration 35
  - impurities 436
  - India 155–6, 169
  - International Conference on Harmonization 20
  - Japan 138, 139
- vaccines 387
- SJS see Stevens-Johnson syndrome
- skin sensitization studies 141
- small business innovation and research (SBIR) 9
- Society of Toxicologic Pathology (STP) 236
- somatropin 76–7
- SOPs see standard operating procedures
- South Africa 99–115
  - application package preparation 104–8
  - application for safety assessment 108–9
  - country information 100–1
  - healthcare and medicines 100–1
  - legal framework 101–2
  - nonclinical safety assessment 109–13
  - pharmacology testing 110
  - registration requirements 101–6
  - registration and review process 106–7
  - regulatory factors 101–7
  - role, structure and organization of the MCC 102–3
  - withdrawals from market 115
- Southern Common Market see MERCOSUR and Brazil
- SPC see Summary of Product Characteristics; Supplementary Protection Certificates
- Special Access Programme (SAP) 78
- species-specific cross-reactivity 280–81, 372
- SPR see surface plasmon resonance
- SRED see Scientific Research and Experimental Development
- SSTC see State Science and Technology Commission
- stability studies 31, 185, 189
- standard operating procedures (SOPs) 132, 148
- standard toxicology studies (STS) 315, 323–5
- Standards Council of Canada (SCC) 66
- State Drug Administration (SDA) 119–21
State Food and Drug Administration (SFDA) 119, 121, 123–33
State Science and Technology Commission (SSTC) 133
STD see severely toxic dose
STDs see sexually transmitted diseases
Stevens-Johnson syndrome (SJS) 334
STP see Society of Toxicologic Pathology
Structural Activity Relationships (SAR) 262
STS see standard toxicology studies
subsequent entry biologics (SEBs) 74–7
sulfanilamide 28, 433
Summary Basis of Decision (SBD) 67–8
Summary Basis for the Registration Application (SBRA) 104, 108, 112
Summary of Product Characteristics (SPC) 83, 112
sunscreen products 82
Supplementary Protection Certificates (SPC) 300
surface plasmon resonance (SPR) 351–2
surrogate molecules 353
systemic exposure threshold 443
systemic hypersensitivity 331
systemic immune complex disease 337–8
T-dependent antibody response (TDAR) assay 325–6, 335–6, 340, 342
T-independent antibody response (TIAR) assay 325
TCR see tissue cross-reactivity
TDAR see T-dependent antibody response
TEN see toxic epidermal necrosis
teratogenicity
developmental and reproductive toxicology 279
Food and Drug Administration 29
impurities 446
India 160
Japan 135–6
MERCOSUR and Brazil 44
TGA see Therapeutic Goods Administration
TG,AC model 245–6
TGN1412 89–90, 93–4
thalidomide 8, 29, 89–90, 135
Therapeutic Goods Administration (TGA) 175–83
Business Process Reform scheme 181–3
clinical trials 186–95
definitions 177
evaluation categories 180–2
evaluation fees and guidelines 183
information supplied to support inclusion of therapeutic goods 178–80
legislative support 176–8
nonclinical data to support clinical trials 188–95
Therapeutic Products Directorate (TPD) 58–60, 71
threshold of toxicological concern (TTC) 262–3
TIAR see T-independent antibody response
tissue cross-reactivity (TCR) 371–3
tissue distribution studies 157–8
topical microbicides 277
toxic epidermal necrosis (TEN) 334
toxicokinetics see pharmacokinetics/toxicokinetics
TPD see Therapeutic Products Directorate
Trade Related Intellectual Property Rights (TRIPS) 145
Traditional Chinese Medicine (TCM) 117, 119–21, 123, 125, 130
transgenic models
biologics 353–4
carcinogenicity studies 244–7
developmental and reproductive toxicology 270, 281
TRIPS see Trade Related Intellectual Property Rights
TTC see threshold of toxicological concern
tumour promotion studies 369–70
type I errors 402–406
type II errors 405
ultraviolet radiation (UVR) 393–6, 399, 404–5, 410–24
see also phototoxicity
unapproved drugs 142
unintended immunomodulation 314–30
United States Pharmacopeia (USP) 432–3, 441
US EPA see Environmental Protection Agency
USP see United States Pharmacopeia
UVR see ultraviolet radiation
vaccines
adjuvants 388
allergy and atopy 382
autism 382–3
Canada 69–70
Index

clinical trials 385–6, 389–90
developmental and reproductive
toxicology 283–9, 388
difference from other
biopharmaceuticals 383
genetic toxicology 389
immune system overload 382
immunotoxicological evaluations 389
international safety regulations 381–92
parameters monitored 387–9
quality testing 384–5
study design 386–7
toxicities attributed to vaccination 381–93
vaginal contraceptives 277–8
vaginal toxicity tests 161

weight-of-evidence approaches 356
WHO see World Health Organization
withdrawals from market 115
women of childbearing potential (WOCBP)
developmental and reproductive
toxicology 273–5, 278, 285
International Conference on
Harmonization 24
nonclinical safety assessment 109–13
World Health Organization (WHO)
386–90
see also International Conference on
Harmonization

yeast test for phototoxicity 400–404